covaxin

New Delhi: Covaxin, India's first indigenous COVID vaccine, will use adjuvant Alhydroxiquim-II to increase immune response, informed Bharat Biotech on Monday. ViroVax LLC, a Kansas based company, has licensed their adjuvant for the use of…

New Delhi: Covaxin, the indigenously developed COVID-19 vaccine, has demonstrated protective efficacy and immunogenicity in non-human primates in Phase I clinical trials in India. Covaxin, which is developed by Bharat Biotech and ICMR, is…

New Delhi: Phase II trials of the indigenously developed COVID-19 vaccine, Covaxin, is likely to begin on Monday, according to a media report on Sunday. Covaxin has been developed by Hyderabad-based Bharat Biotech in collaboration with…

New Delhi: Covaxin, the indigenously developed COVID-19 vaccine, has been found to be safe, according to preliminary results of Phase-I clinical trials. Covaxin is developed by Hyderabad-based Bharat Biotech in collaboration with ICMR and…

New Delhi: AIIMS Delhi will start human trials of Covaxin — country’s first indigenous COVID-19 vaccine — next week with 100 healthy volunteers in the age group of 18-55 years. For a period of 150 days the volunteers will be kept under…

New Delhi: Experts and medicos have criticised the Indian Council of Medical Research’s (ICMR) recent announcement that the indigenous COVID-19 vaccine, COVAXIN, will be available for public use by August 15. The experts said that such a…

Hyderabad: The country's first potential COVID-19 vaccine has received the green light from Drug Controller General of India (DCGI) for Phase I and II human clinical trials. The trials will begin across the country in July. The vaccine,…